GLOW 70 mg

• 1. Overview
• 2. Compound Profiles
• 3. Research Applications
• 4. Pathway / Mechanistic Context
• 5. Preclinical Research Summary
• 6. Form & Analytical Testing
• 7. Referenced Citations
• 8. RUO Disclaimer

Overview

The Glow Blend combines BPC-157 (10mg), TB-500 (10mg), and GHK-Cu (50mg) in a single lyophilized vial. Three compounds, three distinct mechanisms, one format. The rationale is straightforward: researchers studying tissue repair, cellular signaling, and extracellular matrix interactions in parallel don't need three separate sourcing decisions, three separate storage vials, or three separate COAs. The blend format consolidates that.

Each compound operates through a different biological pathway. BPC-157 is a pentadecapeptide studied for angiogenic pathway modulation and nitric oxide system interactions. TB-500 is a synthetic Thymosin Beta-4 analog examined for its actin-binding behavior and effects on cell motility. GHK-Cu is a tripeptide-copper complex with published research on cellular signaling cascades and collagen pathway interactions. None of these mechanisms overlap significantly, which is what makes the combination research-relevant rather than redundant.

All three components in every vial verified by Vanguard Laboratory under a 7-panel conformity protocol (ISO/IEC 17025:2017, A2LA). Per-component purity and identity data documented on the batch-specific COA.

Compound Profiles

BPC-157 (10mg) — Body Protection Compound-157 is a 15-amino acid pentadecapeptide sequence. Molecular formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1419.53 g/mol, CAS 137525-51-0. The sequence was originally isolated from gastric juice proteins and has been studied in cell culture and animal model research for its interactions with angiogenic pathways, nitric oxide signaling, and cellular migration patterns.

TB-500 (10mg) — A synthetic analog of Thymosin Beta-4, a naturally occurring 43-residue polypeptide. Molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S, molecular weight 4963.50 g/mol, CAS 77591-33-4. TB-500 retains the actin-binding domain of the native peptide, which is the structural basis for its studied effects on G-actin sequestration, cell motility, and extracellular matrix interactions in laboratory settings.

GHK-Cu (50mg) — A naturally occurring tripeptide-copper complex (glycyl-L-histidyl-L-lysine copper II). Molecular formula C₁₄H₂₂CuN₆O₄, molecular weight 401.91 g/mol, CAS 49557-75-7. The largest component by mass in the blend. Published research has examined its role in cellular signaling, collagen pathway modulation, and antioxidant system interactions.

Research Applications

• Multi-pathway tissue research examining BPC-157, TB-500, and GHK-Cu interactions in parallel
• Angiogenic pathway studies using BPC-157 in cell-based assay systems
• Actin dynamics and cell motility research using TB-500 as a Thymosin Beta-4 analog
• Nitric oxide system interaction studies with BPC-157 in transfected cell models
• Collagen pathway and extracellular matrix research using GHK-Cu
• Cellular signaling cascade studies examining copper-peptide complex biology
• Comparative mechanism studies across angiogenic, actin-binding, and collagen pathways

All applications are restricted to non-clinical laboratory research environments.

Pathway / Mechanistic Context

BPC-157's published mechanistic research centers on two main areas: nitric oxide system interactions and angiogenic pathway modulation. In cell culture studies, BPC-157 has been shown to influence endothelial nitric oxide synthase (eNOS) activity and downstream nitric oxide production. Angiogenic effects documented in published work include modulation of VEGF expression and effects on endothelial cell migration in scratch assay models.

TB-500's mechanism is built around its actin-binding domain — specifically the sequence LKKTETQ, which is responsible for G-actin sequestration. By modulating the ratio of G-actin to F-actin in cell systems, TB-500 influences cell morphology, motility, and migration in ways that have been characterized in published in vitro studies. The compound also shows interactions with extracellular matrix components in laboratory settings.

GHK-Cu operates through a different set of interactions. The copper component is chelated by the tripeptide backbone, and this copper-peptide structure influences cellular signaling cascades linked in published research to collagen synthesis pathway modulation, antioxidant system interactions, and gene expression changes in cultured fibroblast systems. At 50mg per vial, GHK-Cu is the dominant component by mass in the Glow Blend.

Preclinical Research Summary

BPC-157 has one of the larger preclinical research bases of any compound in the research peptide market. Published work spans cell culture studies and animal model experiments, with focus on angiogenic pathway outcomes and nitric oxide system interactions. Chang et al. (2011, Journal of Applied Physiology) examined BPC-157 effects on tendon outgrowth, cell survival, and cell migration, documenting histological outcomes in tissue repair assays.

TB-500 research has focused on the Thymosin Beta-4 framework, with TB-500 used as the synthetic research analog. Goldstein et al. have published extensively on Thymosin Beta-4 biology, including work on actin dynamics and cell motility mechanisms. The compound's interactions with extracellular matrix components and growth factor signaling pathways have been characterized in published in vitro studies.

GHK-Cu has a published research record going back several decades. Pickart and colleagues documented the copper-peptide complex's interactions with collagen synthesis pathways and skin fibroblast behavior in cell culture systems. More recent published work expanded into gene expression analysis, with studies documenting GHK-Cu effects on large gene expression datasets in cultured cell systems.

Form & Analytical Testing

The Glow Blend is supplied as research-grade lyophilized powder containing all three components pre-blended per vial: BPC-157 (10mg), TB-500 (10mg), GHK-Cu (50mg), 70mg total. Each batch is submitted to Vanguard Laboratory for conformity testing using a 5-vial protocol. Blends require identity confirmation and purity analysis for each component separately — the 7-panel conformity protocol covers identity verification for all three compounds, purity analysis (≥98% per component via HPLC), net content verification, endotoxin levels, heavy metals, and sterility. Per-component purity and identity data is published on the batch-specific COA. Full COAs are on our COA Library and linked via QR code on each vial.

Referenced Citations

1. Chang CH et al., “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J Appl Physiol, 2011 110(3):774–780.
2. Goldstein AL et al., “Thymosin β4: a multifunctional regenerative peptide,” Ann N Y Acad Sci, 2012 1270:83–89.
3. Pickart L et al., “The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging,” Rejuvenation Res, 2012 15(2):236–239.
4. Pickart L et al., “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration,” Biomed Res Int, 2015 648108.
5. Hsieh MJ et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J Mol Med, 2017 95(3):323–333.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic. No statements on this website have been evaluated by the FDA. You must be 21 years or older to purchase.

Batch COA: In Progress

This batch is currently undergoing conformity testing at Vanguard Laboratory. For the Glow Blend, the full Certificate of Analysis documents identity and purity for each component separately — BPC-157, TB-500, and GHK-Cu — along with net content, endotoxins, heavy metals, and sterility across all three. The COA will be published here and linked via QR code on each vial when testing is complete.

We don't ship product before results are in. When the COA is live, you'll find it here and on our COA Library.